The study was designed to create a primary cell culture of uveal melanoma and to evaluate its resistance to chemotherapy. Of the obtained 20 samples of uveal melanoma, the primary cultures with proliferation sufficient for MTT test were derived in only 7 cases. However, even these cultures were unable to survive more than 4 passages; the cells accumulated melanin and underwent apoptosis. Retinol palmitate and nepafenac produced no cytotoxic effect on uveal melanoma cells. Of 5 cultures treated with sodium valproate (Convulex), no pronounced cytotoxic effect was observed in one culture (UM4); in 2 cultures, 50% cells died in the presence of the lowest drug concentration of 1.88 mg/ml; and in 2 cultures, the same effect was achieved at drug concentrations 7-10 mg/ml. The cytotoxic effect of treosulfan was evaluated in only 4 cultures of uveal melanoma: the drug exhibited pronounced antitumor activity on all cultures, in 2 cases, it was effective at a concentration of 0.16 mg/ml. Gemcitabine in a concentration of 2.5 mg/ml produced a pronounced cytotoxic effect in 4 out of 7 cultures (death of 70-80% cells) and induced death of ~45% cells in the remaining 3 cultures. Mitoxantrone had ambiguous effect: in 2 of 5 cultures, the drug in high concentrations stimulated the growth of tumor cells, but in 3 cultures, the drug even in minimum concentrations induced death of 70-80% cells.
Similar content being viewed by others
References
Grishina EE, Lerner MYu, Gemdzhian EG. Epidemiology of uveal melanomas in Moscow. Al’manakh Klin. Med. 2017;45(4):321-325. Russian.
Saakyan SV, Amiryan AG, Tsygankov AYu, Loginov VI, Burdennyy AM. Mutations in oncogenes GNAQ and GNA11 in uveal melanoma patients. Mol. Med. 2014;(2):34-37. Russian.
Álvarez-Rodríguez B, Latorre A, Posch C, Somoza Á. Recent advances in uveal melanoma treatment. Med. Res. Rev. 2017;37(6):1350-1372.
Angi M, Versluis M, Kalirai H. Culturing uveal melanoma cells. Ocul. Oncol. Pathol. 2015;1(3):126-132.
Atzpodien J, Terfloth K, Fluck M, Reitz M. Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients. Cancer Chemother. Pharmacol. 2008;62(4):685-688.
Becker JC, Kämpgen E, Bröcker E. Classical chemotherapy for metastatic melanoma. Clin. Exp. Dermatol. 2000;25(6):503-508.
Collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS). COMS report No. 15. Arch. Ophthalmol. 2001;119(5):670-676.
Landreville S, Agapova OA, Matatall KA, Kneass ZT, Onken MD, Lee RS, Bowcock AM, Harbour JW. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin. Cancer Res. 2012;18(2):408-416.
Leyvraz S, Spataro V, Bauer J, Pampallona S, Salmon R, Dorval T, Meuli R, Gillet M, Lejeune F, Zografos L. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J. Clin. Oncol. 1997;15(7):2589-2595.
Marshall JC, Fernandes BF, Di Cesare S, Maloney SC, Logan PT, Antecka E, Burnier MN Jr. The use of a cyclooxygenase-2 inhibitor (Nepafenac) in an ocular and metastatic animal model of uveal melanoma. Carcinogenesis. 2007;28(9):2053-2058.
McNamara M, Clynes M, Dunne B, NicAmhlaoibh R, Lee WR, Barnes C, Kennedy SM. Multidrug resistance in ocular melanoma. Br. J. Ophthalmol. 1996;80(11):1009-1012.
Moschos MM, Dettoraki M, Androudi S, Kalogeropoulos D, Lavaris A, Garmpis N, Damaskos C, Garmpi A, Tsatsos M. The role of histone deacetylase inhibitors in uveal melanoma: current evidence. Anticancer Res. 2018;38(7):3817-3824.
Nayman T, Bostan C, Logan P, Burnier MN Jr. Uveal melanoma risk factors: a systematic review of meta-analyses. Curr. Eye Res. 2017;42(8):1085-1093.
Neale MH, Myatt N, Cree IA, Kurbacher CM, Foss AJ, Hungerford JL, Plowman PN. Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside. Br. J. Cancer. 1999;79(9-10):1487-1493.
Saakyan SV, Tsygankov АY, Moiseeva NI, Karamysheva АF, Zhil’tsova MG, Tadevosyan SS. Retinoblastoma cell culturing and evaluation of their drug resistance. Bull. Exp. Biol. Med. 2018;165(1):148-153.
Salmon RJ, Levy C, Plancher C, Dorval T, Desjardins L, Leyvraz S, Pouillart P, Schlienger P, Servois V, Asselain B. Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapy. Eur. J. Surg. Oncol. 1998;24(2):127-130.
Schmittel A, Schmidt-Hieber M, Martus P, Bechrakis NE, Schuster R, Siehl JM, Foerster MH, Thiel E, Keilholz U. A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. Ann. Oncol. 2006;17(12):1826-1829.
Shields CL, Kaliki S, Livesey M, Walker B, Garoon R, Bucci M, Feinstein E, Pesch A, Gonzalez C, Lally SE, Mashayekhi A, Shields JA. Association of ocular and oculodermal melanocytosis with the rate of uveal melanoma metastasis: analysis of 7872 consecutive eyes. JAMA Ophthalmol. 2013;131(8):993-1003.
Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118(9):1881-1885.
Terheyden P, Bröcker EB, Becker JC. Clinical evaluation of in vitro chemosensitivity testing: the example of uveal melanoma. J. Cancer Res. Clin. Oncol. 2004;130(7):395-399.
Vertuani S, Dubrovska E, Levitsky V, Jager MJ, Kiessling R, Levitskaya J. Retinoic acid elicits cytostatic, cytotoxic and immunomodulatory effects on uveal melanoma cells. Cancer Immunol. Immunother. 2007;56(2):193-204.
Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, Crocetti E, Lutz JM, Paci E; EUROCARE Working Group. Incidence of uveal melanoma in Europe. Ophthalmology. 2007;114(12):2309-2315.
Yonekawa Y, Kim IK. Epidemiology and management of uveal melanoma. Hematol. Oncol. Clin. North Am. 2012;26(6):1169-1184.
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Kletochnye Tekhnologii v Biologii i Meditsine, No. 3, pp. 185-190, September, 2020
Rights and permissions
About this article
Cite this article
Saakyan, S.V., Tsygankov, А.Y., Moiseeva, N.I. et al. Assessment of the Chemosensitivity of Uveal Melanoma Cells Ex Vivo. Bull Exp Biol Med 170, 142–147 (2020). https://doi.org/10.1007/s10517-020-05020-3
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-020-05020-3